logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
after Q1 2018
Dermira Inc.
Topline results from phase 3 trial of Olumacostat glasaretil (CLAREOS-2)
Acne
Jan 2018
Kadmon Holdings LLC
Initial data from phase 2 trial of KD025
Idiopathic pulmonary fibrosis
before Q1 2018
Axsome Therapeutics, Inc.
Interim analysis results from phase 3 trial of AXS-02 ( COAST-1)
Knee OA associated with associated with bone marrow lesions
before Q1 2018
Axsome Therapeutics, Inc.
Interim analysis results from phase 3 trial of AXS-02 ( CREATE-1 )
Complex Regional Pain Syndrome
after Q1 2018
Axsome Therapeutics, Inc.
Top line data from phase 3 trial of AXS-05 (STRIDE-1)
Treatment resistant depression (TRD)
2018
Conatus Pharmaceuticals Inc
Results from Phase 2b trial of Emricasan (ENCORE-PH)
Liver cirrhosis caused by nonalcoholic steatohepatitis
2018
Conatus Pharmaceuticals Inc
Results from Phase 2b trial of Emricasan (ENCORE-NF)
NASH fibrosis
2018
MERRIMACK PHARMACEUTICALS, INC.
Results from phase 2 study of MM-121
Advanced or metastatic non-small cell lung cancer.
Early 2018
Prothena Corporation plc
Topline results from phase 2b trial of NEOD001 (PRONTO)
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Q1 2018
Galmed Pharmaceuticals Ltd.
Interim data from phase IIa study of Aramchol (ARRIVE)
HIV-associated lipodystrophy and nonalcoholic fatty liver disease
2018
Xencor Inc
Initial data from phase 2 study of XmAb5871
Systemic lupus erythematosus
Early 2018
Alnylam Pharmaceuticals Inc.
Top Line Data from ENDEAVOUR Phase 3 Study with Revusiran
Treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM) (familial amyloidotic cardiomyopathy)
after Q1 2018
Eleven Biotherapeutics, Inc.
Topline data from phase 3 trial of Vicinium
high-grade non-muscle invasive bladder cancer
after Q1 2018
Ocular Therapeutix Inc.
Topline results from 1st phase 3 trial of OTX-TP
Glaucoma and Ocular Hypertension
Early 2018
Auris Medical Holding AG
Topline results from 2nd phase 3 study of Keyzilen (TACTT3)
acute inner ear tinnitus.
2018
Versartis Inc.
Topline data from phase 3 Japanese trial of Somavaratan
growth hormone deficiency
after Q1 2018
ALDER BIOPHARMACEUTICALS INC
Topline data from phase 3 study of ALD403 (PROMISE 2)
chronic migraine
Q1 2018
Strongbridge Biopharma plc
Topline data from phase 3 trial of COR-003 (SONICS)
endogenous Cushing’s syndrome
after Q1 2018
Dermira Inc.
Topline results from phase 3 trial of Olumacostat glasaretil (CLAREOS-1 )
Acne
Early 2018
Pluristem Therapeutics, Inc.
Top line results from phase 2 trial of PLX-PAD
intermittent claudication (IC), a peripheral artery disease (
Q1 2018
SAGE Therapeutics, Inc.
Top-line data from Phase 2 trial of SAGE-217
postpartum depression
Dec 2017
GALECTIN THERAPEUTICS INC
Topline data from phase II study with GR-MD-02 (NASH-CX)
NASH with cirrhosis
Q4 2017
EYEGATE PHARMACEUTICALS INC
Topline data from confirmatory Phase 3 trial of EGP-437 combination product
Non-infectious anterior uveitis;
Q4 2017
Aquinox Pharmaceuticals, Inc.
Top-line data from first Phase 3 trial of AQX-1125
Interstitial cystitis/bladder pain syndrome
Q4 2017
Arena Pharmaceutical Inc.
Data from phase 2 study of Etrasimod
ulcerative colitis